Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic.

Presentations were received from:

Derek Leishman (VP Translational and Quantitative Toxicology at Eli Lilly and Company) presented the opportunities a sponsor now has available to increase the efficiency and effectiveness of QTc assessment by leveraging the ICH S7B core assays. He also discussed times when the already conducted core hERG and in vivo assays do not meet the new expected ‘best practice’, and addressed how gaps in best practice or limitations in tested exposures could be mitigated.

Steve Jenkinson (VP Drug Discovery and Safety at Metrion) described a model utilizing a voltage sensitive dye in combination with a fast capture rate plate reader to generate high quality action potential recordings in a 96 well based format. Moreover, using an extensive and robust reference data set, the translation of key endpoints from this assay allows the prediction of compound plasma exposures in the clinic that will be associated with a 10 ms change in QTc for novel preclinical compounds, as well as provide an insight into the probability of potential QRS liabilities.

Questions from delegates with answers from the presenters, and a link to download the webinar, are provided: https://www.metrionbiosciences.com/cardiac-risk-recording/